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Schmallenberg virus (SBV) is a newly emerged orthobunyavirus that has caused widespread
disease in cattle, sheep and goats in Europe. Like other orthobunyaviruses, SBV is characterized
by a tripartite negative-sense RNA genome that encodes four structural and two non-structural
proteins. This study showed that SBV has a wide in vitro host range, and that BHK-21 cells are a
convenient host for both SBV propagation and assay by plaque titration. The SBV genome
segments were cloned as cDNA and a three-plasmid rescue system was established to recover
infectious virus. Recombinant virus behaved similarly in cell culture to authentic virus. The ORF for
the non-structural NSs protein, encoded on the smallest genome segment, was disrupted by
introduction of translation stop codons in the appropriate cDNA, and when this plasmid was used
in reverse genetics, a recombinant virus that lacked NSs expression was recovered. This virus had
reduced capacity to shut-off host-cell protein synthesis compared with the wild-type virus. In
addition, the NSs-deleted virus induced interferon (IFN) in cells, indicating that, like other
orthobunyaviruses, NSs functions as an IFN antagonist, most probably by globally inhibiting host-
cell metabolism. The development of a robust reverse genetics system for SBV will facilitate
investigation of its pathogenic mechanisms as well as the creation of attenuated strains that could
be candidate vaccines.
INTRODUCTION
The family Bunyaviridae has provided many examples of
emerging and re-emerging diseases, such as those caused by
Sin Nombre hantavirus in North America, Rift Valley fever
phlebovirus in Africa and the Arabian peninsula, Crimean–
Congo hemorrhagic fever nairovirus in Turkey and severe
fever with thrombocytopenia phlebovirus in China
(reviewed by Elliott, 1997, 2009; Feldmann, 2011). In
2011, yet another new bunyavirus appeared, this time in
Europe. Farms in Germany and the Netherlands reported a
disease in cattle causing transient fever, diarrhoea, loss of
condition and a reduction in milk yield. Animals recovered
within a few days. Towards the end of 2011, reports of
abortion, stillbirths and offspring with congenital abnor-
malities appeared from cattle, sheep and goat herds
(Garigliany et al., 2012; Tarlinton et al., 2012).
Researchers at the Friedrich-Loeffler Institute in Germany
determined the pathogen, by metagenomic analysis, to be
an orthobunyavirus of the Simbu serogroup, and named it
Schmallenberg virus (SBV) after the town where the first
isolation was made (Hoffmann et al., 2012).
The genus Orthobunyavirus is one of five genera that
currently comprise the family Bunyaviridae, the others
being Hantavirus, Nairovirus, Phlebovirus and Tospovirus
(Plyusnin et al., 2012). Bunyaviruses are characterized by
the possession of a tripartite negative-sense ssRNA genome
that encodes four structural proteins. The large (L)
segment encodes the viral RNA-dependent RNA polymer-
ase or L protein, the medium (M) segment encodes the
virion glycoproteins Gn and Gc, and the small (S) segment
encodes the nucleoprotein (N). Non-structural proteins are
encoded by some viruses on the M (NSm protein) and by
some on the S (NSs protein) segment. There are differences
in the sizes of RNAs and proteins in viruses belonging to
the different genera, and in addition all viruses within a
genus share the same consensus terminal sequence on each
RNA segment of the genome (Plyusnin & Elliott, 2011;
Plyusnin et al., 2012). The genus Orthobunyavirus contains
at least 170 named viruses that have been conveniently
divided among 18 serogroups on the basis of cross-
reactivity in complement fixation, neutralization andA supplementary table is available with the online version of this paper.
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haemagglutination-inhibition assays (Bishop, 1990;
Calisher, 1996; Elliott & Blakqori, 2011). The Simbu
serogroup contains 25 viruses, of which Akabane, Aino,
Sathuperi, Peaton, Shamonda and Shuni viruses are known
to be teratogenic in ruminants in Africa, Asia and Australia
(Calisher, 1996). SBV represents the first Simbu serogroup
virus that has been reported in Europe. Simbu serogroup
viruses are transmitted by midges and mosquitoes, and
analysis of midges trapped in Denmark and Belgium has
shown evidence of SBV infection (De Regge et al., 2012;
Rasmussen et al., 2012). SBV appears to have survived the
2011/2012 winter in Europe, and at least 12 European
countries have now reported SBV infections, involving
around 5000 holdings (Beer et al., 2013; European Food
Safety Authority, 2012). No vaccine is yet available.
Previous work from our laboratory established a reverse
genetic system for the prototype orthobunyavirus,
Bunyamwera virus (BUNV) (Bridgen & Elliott, 1996;
Lowen et al., 2004), using the bacteriophage T7 RNA
polymerase system, whereby infectious virus could be
generated entirely from cDNA clones. Subsequently, the
system has been applied to the orthobunyavirus La Crosse
virus (LACV) and the phlebovirus Rift Valley fever virus
(RVFV) (Billecocq et al., 2008; Blakqori & Weber, 2005;
Gerrard et al., 2007; Habjan et al., 2008; Ikegami et al.,
2006). In addition, recovery of Akabane virus has been
achieved using the RNA polymerase I approach (Ogawa
et al., 2007). One exploitation of reverse genetics is the
creation of genetically engineered recombinant viruses that
have potential as candidate vaccines (Bird et al., 2011;
Brennan et al., 2011; Lowen et al., 2005). Therefore, as a
future tool to develop vaccine strains for SBV, we have
reported here the establishment of an efficient reverse
genetic system.
RESULTS AND DISCUSSION
Growth of SBV in mammalian cell lines
The initial stock of SBV (isolate BH80/11-4) had been
passaged once in Culicoides KC cells and twice in baby
hamster kidney (BHK) cells. An aliquot was used for
plaque purification in BHK-21 cells and working stocks
were grown in BHK-21 cells for further study. The in vitro
host range was investigated in a range of cell lines infected
at both high (5 p.f.u. per cell) and low (0.05 p.f.u. per cell)
m.o.i, by incubating the infected cells at 37 uC for 48 h and
then titrating the yield of virus on BHK-21 cells (Table 1).
SBV grew productively in all cell lines tested, irrespective of
the species of origin, although with varying degrees of
efficiency. The highest titres of virus were obtained in
BHK-21 (hamster) and HuH7 (human) cells after infection
at low m.o.i.; slightly lower titres were achieved in these
cells when infected at high m.o.i. Vero E6 (monkey) and
CPT-Tert (sheep) cells also generated high yields of virus,
although in Vero E6 cells no difference in yield was
observed between high and low m.o.i., whereas in the sheep
cells the yield was greater from cells infected at high m.o.i.
The other human cell lines were less productive and,
interestingly, the Madin–Darby bovine kidney (MDBK)
(bovine) cell line was also less efficient for SBV growth.
Previous studies on BUNV and Marituba orthobunyavirus
(Kascsak & Lyons, 1978; Volkmer et al., 1983) showed
yields of virus from mammalian cells to be multiplicity
dependent, and that the ease with which defective-
interfering particles were generated was cell dependent.
Thus, for BUNV, virus yields were greater from BHK-21
and Vero cells infected at low m.o.i. than at high m.o.i.,
whereas for MDBK cells, yields were directly correlated
with the input multiplicity. SBV behaved similarly to
BUNV in BHK-21 and MDBK cells, although not in Vero
E6 cells (Table 1); the generation of defective-interfering
particles was not investigated.
The ability of SBV to form plaques in the different cell lines
was also studied. Marked differences in plaque morphology
were noted, with the largest and clearest plaques produced
in BHK-21 cells (Fig. 1a–d). Plaques were much smaller in
Vero E6 cells, a line that is used routinely to propagate
orthobunyaviruses. Of note was the fact that plaques were
also smaller in BSR-T7/5 cells, a BHK cell-derived line that
constitutively expresses T7 RNA polymerase (Buchholz
et al., 1999). Easily discernible plaques were also formed in
CPT-Tert cells, although in all other tested cell lines
plaques were very small after 3 days (Table 1). Therefore,
for routine use, plaque assays were carried out in BHK-21
cells.
Cloning the SBV genome
The sequences of the SBV genome segments (isolate BH80/
11-4) (GenBank accession nos HE649912–HE649914;
Hoffmann et al., 2012) mostly lack the terminal consensus
nucleotides characteristic of orthobunyavirus RNAs
(Plyusnin et al., 2012). For the M segment, the 39
consensus sequence is present in the database entry but
there are additional nucleotides thereafter, which we
presumed to be artefacts generated during the assembly
process to produce full-length sequences. By comparison
with the available sequences in the databases for other
Simbu serogroup viruses, the missing bases were predicted,
and segment-specific oligonucleotides were designed
(Table S1, available in JGV Online) to amplify complete
cDNAs by RT-PCR. Amplified DNA products of approxi-
mately 0.8, 4.4 and 6.9 kb were obtained (Fig. 2a) and
cloned into plasmid TVT7R(0,0) (Johnson et al., 2000)
such that the antigenome-sense RNA would be transcribed
by T7 RNA polymerase. The complete nucleotide
sequences of the cDNA clones were determined and exactly
matched the database sequences.
The plasmids were then used in a three-plasmid rescue
system (Lowen et al., 2004) by transfection into T7 RNA
polymerase-expressing BSR-T7/5 cells. Full-length anti-
genome-sense RNAs having exact ends are transcribed in
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the cytoplasm of these cells and, although apparently
neither 59 capped nor 39 polyadenylated, the RNAs can be
translated to give viral proteins. Presumably, the N
protein is then able to interact with the RNAs to generate
ribonucleoproteins, which can be replicated by the
expressed SBV polymerase to initiate the infectious cycle.
The supernatant medium was harvested at 5 days post-
transfection and used in a plaque assay in BHK-21 cells.
Cells transfected with the mixture of three plasmids
yielded a titre of 1.156106 p.f.u., whereas no virus was
recovered from a transfection lacking the L segment
cDNA. The plaque morphology of the recombinant virus
(rSBV) was indistinguishable from that of authentic virus
(Fig. 1e). The rescue of SBV from cDNA was repeated
several times and always generated virus. The complete
nucleotide sequence of rSBV was determined and matched
that of the parental plasmids. Thus, SBV, like BUNV,
LACV and RVFV, can be recovered from cDNAs
expressing full-length antigenome-sense RNAs without
the need for ‘helper’ plasmids that express viral proteins
independently (Elliott, 2012).
The NSs proteins of BUNV and LACV are the major
virulence determinants and act as interferon (IFN)
antagonists by blocking cellular RNA polymerase II-driven
transcription (reviewed by Elliott & Blakqori, 2011). To
determine whether the NSs protein of SBV might have a
similar role, a recombinant virus was created lacking NSs
expression. Previously, we generated an NSs deletion
mutant of BUNV by mutation of the NSs start codon,
but this resulted in either expression of NSs-related
proteins initiated from AUG codons downstream of the
authentic start codon or the generation of a mutation that
introduced a new AUG codon, resulting in an N-terminally
deleted NSs protein (Hart et al., 2009; van Knippenberg
et al., 2010). Therefore, a different strategy was used
whereby three translational stop codons were introduced in
the NSs ORF at codons 14, 17 and 20 (CAA at nt 96,
GAA at nt 10, and TAA at nt 115 in the S segment) such
that the amino acid sequence of the overlapping N protein
remained unchanged (Fig. 2b). This scheme would allow
translation initiation at the NSs start codon and potentially
the production of an 11 aa peptide only, but there should
not be further ribosome scanning to downstream AUG
codons. The NSs-deleted S segment cDNA was co-
transfected with L- and M-segment cDNAs into BSR-T7/
5 cells, and the medium (containing recombinant virus,
which was named rSBVdelNSs) was harvested 5 days after
transfection for use in a plaque assay in BHK-21 cells. The
plaques were stained after 3 days and were noticeably
smaller and less distinct than plaques produced by the
wild-type virus (Fig. 1f). The yield was about 16105 p.f.u.
The nucleotide sequence of the recovered virus was
determined and the mutations in the S segment were
confirmed (Fig. 2c).
Table 1. Growth of SBV in various mammalian cell lines
Cell line (host) Yield from high m.o.i.* Yield from low m.o.i.D Plaque phenotyped
BHK-21 (hamster) 3.06107 1.16108 3 mm, clear
BSR-T7/5 (hamster) 8.56105 1.56107 1 mm, clear
A549 (human) 1.46106 3.06105 1 mm, clear
HuH7 (human) 1.16107 1.06108 1–2 mm, cloudy
HeLa (human) 6.06105 4.56104 Indistinct
Hep2 (human) 7.06103 6.56103 Indistinct
MDBK (cow) 4.56105 9.06103 Indistinct
MDCK (dog) 1.46105 6.06106 0.5 mm, clear
Vero E6 (monkey) 1.16107 1.16107 1 mm, clear
CPT-Tert (sheep) 3.06107 3.06106 1.5–2 mm, clear
*Yield in p.f.u. ml21 from cells infected at an m.o.i. of 5 and titrated in BHK-21 cells.
DYield in p.f.u. ml21 from cells infected at an m.o.i. of 0.05 and titrated in BHK-21 cells.
dSize and appearance of plaques after 3 days incubation at 37 uC.
(a) (b) (c)
(d) (e) (f)
Fig. 1. Plaque phenotypes of SBV in different cell lines. Infected
cells were fixed after 3 days incubation at 37 6C and stained with
crystal violet. (a–d) Wild-type (authentic) SBV in BHK-21 (a),
BSR-T7/5 (b), Vero E6 (c) and CPT-Tert (d) cells; (e) rSBV in
BHK-21 cells; (f) rSBVdelNSs in BHK-21 cells.
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S     1 kb            M    1 kb           L   1 kb
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(a)
T7 promoter
5′ 3′
cDNA
Hepatitis delta 
ribozyme
T7 terminator
T7 transcription
Self-cleavage by
ribozyme
5′ UTR 3′ UTR  
Antigenome-sense RNA
(b)
 
atgtcaagccaattcatttttgaagatgtaccacaacggaatgcagctacatttaacccggaggtcgggtatgtggcatttattggtaa
N
NSs
M S  S  Q  F  I  F  E  D  V  P  Q  R  N  A  A  T  F  N  P  E  V  G  Y  V  A  F  I  G  K
M Y  H  N  G  M Q  L  H  L  T  R  R  S  G  M W  H  L  L  V  S 
pTVTSBVS
atgtcaagccaattcatttttgaagatgtaccacaacggaatgcagctacatttaacccggaggtagggtatgtagcatttataggtaa
N
NSs
M S  S  Q  F  I  F  E  D  V  P  Q  R  N  A  A  T  F  N  P  E  V  G  Y  V  A  F  I  G  K
M Y  H  N  G  M Q  L  H  L  T  R  R  * G  M * H  L  * V  S 
pTVTSBVS-delNSs3Stop
40                            50                         60                         70                         80            90                        100                      110
(c)
Fig. 2. Production of cDNA clones. (a) Full-length RT-PCR products derived from the S, M and L segments as indicated. The
amplified DNAs were separated by electrophoresis on agarose gels along with DNA markers (1 kb ladder; Promega), with the
relevant fragment sizes indicated. (b) Schematic of the pTVT series of plasmids (see Methods), showing transcription by T7
RNA polymerase and processing by the hepatitis delta ribozyme to generate antigenome-sense SBV RNAs having the correct
39 ends. (c) S segment cDNA sequences. The nucleotide sequence encompassing the N and NSs start codons (methionine, M)
is shown and the positions of the mutations used to introduce translational stop codons (asterisks) in the NSs ORF are
indicated. Numbers are nucleotide positions in the full-length S segment cDNA.
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Growth properties of authentic and recombinant
viruses in mammalian cells
Growth curves of authentic SBV (hereafter designated
wtSBV), rSBV and rSBVdelNSs were compared in BHK-21,
CPT-Tert and A549 cells infected at an m.o.i. of 3 and
maintained at 37 uC (Fig. 3). Essentially no difference in
growth kinetics was observed between wtSBV and rSBV in
any of the cell lines, although the growth in A549 cells was
less efficient than in the other two lines. In BHK-21 cells,
rSBVdelNSs grew similarly to wtSBV or rSBV until 36 h
p.i. but did not achieve as high a titre at 48 h p.i., whereas
in CPT-Tert cells the mutant virus grew slightly slower
than wtSBV or rSBV. However, in A549 cells, which are
known to have a competent IFN system, the growth of
rSBVdelNSs appeared to be more restricted after 12 h p.i.,
and the titre at 24 h p.i. was more than tenfold lower than
the genetically intact viruses.
Protein synthesis by authentic and recombinant
viruses in mammalian cells
The production of viral N protein by the different viruses
in BHK-21, CPT-Tert and A549 cells was monitored by
Western blotting using a monospecific antibody raised
against bacterially expressed SBV N protein; detection of
tubulin was used as a loading control (Fig. 4a). N was
clearly detected at 8 h p.i. in all cell lines infected with all
viruses. Although the blots were not quantitative, the
amount of N appeared to be slightly lower in A549 cells
compared with BHK-21 or CPT-Tert cells. Overall, no
marked differences in the kinetics of N accumulation were
seen in cells infected with wtSBV or the recombinant
viruses.
BHK-21 cells infected with the three viruses were also
radiolabelled at different times after infection with
[35S]methionine and cell extracts were analysed by SDS-
PAGE. Both authentic and recombinant wild-type viruses
induced significant shut-off of host-cell protein synthesis
by 24 h p.i., and two prominent bands most likely
corresponding to the viral Gc and N proteins were
apparent. No shut-off was observed in cells infected with
rSBVdelNSs (Fig. 4b). Thus, the accumulated data
indicated that the mutant virus lacking NSs behaved
similarly to other orthobunyaviruses that do not produce
the S-segment-encoded NS protein.
Replication in mosquito cells
Other Simbu group viruses have been isolated from both
culicoid midges and various species of mosquito (Calisher,
1996). SBV has been shown to grow in Culicoides
variipennis larvae cells (KC cells; Hoffmann et al., 2012),
and here we investigated whether cultured mosquito cells
would also be permissive. Therefore, we infected Aedes
albopictus C6/36 cells with rSBV or rSBVdelNSs, titrated
the virus released into the supernatant by plaque assay and
monitored the production of viral N by Western blotting.
Both viruses grew with similar kinetics, achieving titres in
excess of 107 p.f.u. ml21 by 48 h p.i. (Fig. 5a). However, no
cytopathic effect (CPE) was apparent in the cells at any
stage after infection with either virus. N was first detected
at 18 h p.i. for both viruses, and accumulated thereafter in
a similar manner (Fig. 5b). These results indicated that
SBV can grow productively in A. albopictus C6/36 cells and
that the NSs protein is not required, and thus SBV behaves
similarly to BUNV in this cell line (Szemiel et al., 2012).
The ability of SBV to replicate in other mosquito cell lines
or to replicate in and be transmitted by live mosquitoes
awaits further investigation.
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Fig. 3. Virus growth curves. BHK-21, CPT-Tert or A549 cells were
infected with wtSBV, rSBV or rSBVdelNSs at an m.o.i. of 3 and
incubated at 37 6C. The titre of virus released into the supernatant
at different times post-infection (p.i.) was determined by plaque
assay in BHK-21 cells.
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IFN induction by recombinant viruses
A biological assay used previously to monitor IFN
production in response to orthobunyavirus infection
(Mohamed et al., 2009) was employed here to investigate
IFN induction by rSBV and rSBVdelNSs. A549 and CPT-
Tert cells were infected with recombinant viruses and UV-
inactivated medium from the cells was used to treat fresh
A549 or CPT-Tert reporter cells; if IFN was present in the
medium, an antiviral state would be induced and the cells
would be protected from subsequent infection with
encephalomyocarditis virus (EMCV). Recombinant
BUNV (rBUNV) and BUNV with the NSs deleted
(rBUNVdelNSs2 ) were used as controls. The relative
amounts of IFN produced were calculated according to the
highest dilution of supernatant affording protection to the
cells from EMCV infection. As shown in Fig. 6, medium
from A549 cells infected with wild-type viruses showed
relatively little IFN production. By contrast, medium from
rSBVdelNSs- or rBUNVdelNSs2-infected cells largely
protected the reporter from EMCV infection, indicating
significant induction of IFN in the initial infections. Thus,
rSBVdelNSs, like its BUNV counterpart rBUNVdelNSs2
lacking NSs, is an IFN inducer, implying that the NSs
protein functions as an IFN antagonist. However, no
protection against EMCV infection was noted in sheep
cells treated with medium from either rSBVdelNSs- or
m   4   8  12 16 24   4   8  12 16 24   4  8 12 16 24
wtSBV rSBV rSBVdelNSs
m   4   8  12 16 24   4   8  12 16 24  4   8 12 16 24
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m   4   8  12 16 24   4   8  12 16 24  4  8  12 16 24
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CPT-Tert
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N
N
N
N
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m     6    12     24     6     12    24    6     12     24   h p .i.
wtSBV rSBV rSBVdelNSs
b
(a)
(b)
h p.i.
h p.i.
h p.i.
Fig. 4. Viral protein synthesis in mammalian cells. (a) N production.
BHK-21, CPT-Tert or A549 cells were infected with wtSBV, rSBV
or rSBVdelNSs at an m.o.i. of 3 and incubated at 37 6C. Cell lysates
were prepared at different times after infection, and proteins were
separated by SDS-PAGE and transferred to nitrocellulose mem-
brane. Accumulation of viral N was detected by reaction with anti-N
antibody, and detection of tubulin (tub) was used as a loading
control. (b) Host-cell protein shut-off. BHK-21 cells were infected
with wtSBV, rSBV or rSBVdelNSs at an m.o.i. of 3 and incubated at
37 6C. At different times p.i., the cells were labelled for 1 h with
[35S]methionine and cell extracts were fractionated by SDS-PAGE.
The dried gel was exposed to X-ray film. The positions of viral Gc
and N are indicated. m, Mock-infected cells.
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Fig. 5. Replication in mosquito cells. (a) Growth kinetics. A.
albopictus C6/36 cells were infected with rSBV or rSBVdelNSs at
an m.o.i. of 3 and incubated at 28 6C. The amount of virus released
into the supernatant at different times p.i. was determined by
plaque assay in BHK-21 cells. (b) N production. Cells were
infected as above and lysates were prepared at different times p.i.
Proteins were separated by SDS-PAGE and transferred to
nitrocellulose membrane. Accumulation of viral N protein was
detected by reaction with anti-N antibody, and detection of tubulin
(tub) was used as a loading control. m, Mock-infected cells.
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rBUNVdelNSs2-infected CPT-Tert cells (data not shown),
indicating that CPT-Tert cells are incapable of producing
IFN, although they have previously been shown to respond
to exogenously applied IFN (Ratinier et al., 2011).
Concluding remarks
SBV has a typical orthobunyavirus genetic organization
and behaves similarly to many other orthobunyaviruses in
terms of growth characteristics in mammalian cell lines.
Wild-type SBV caused shut-off of host-cell protein
synthesis in mammalian cells and, as described previously
for BUNV and LACV, this property was associated with
expression of the NSs protein. In addition, in IFN-
competent cells, the NSs-deleted virus induced IFN
production, whereas this was not the case in wild-type
virus-infected cells. Thus, NSs acts as the viral IFN
antagonist.
SBV is still spreading throughout Europe, although the full
extent will not be apparent until the 2012/2013 lambing
season. Experience with other Simbu serogroup viruses
suggests that vaccination could be a useful control measure
(Kim et al., 2011). The relative ease with which a reverse
genetics system was established for SBV, and the robustness
of both wild-type and NSs-deleted virus recovery, indicate
that the system can be exploited to generate further
recombinant viruses that could be potential live-attenuated
vaccines. Previously, we described how rearrangement of
the non-coding/coding sequences (Lowen et al., 2005) or
deletions within the non-coding sequences (Lowen &
Elliott, 2005; Mazel-Sanchez & Elliott, 2012) of the BUNV
genome attenuated virus replication. Similar approaches
are under investigation in order to generate attenuated SBV
strains.
METHODS
Cells. BHK-21 cells were grown in Glasgow’s minimal essential
medium (GMEM) supplemented with 10% tryptose phosphate broth
(TPB) and 10% newborn calf serum (NCS). BSR-T7/5 cells, which
stably express T7 RNA polymerase (Buchholz et al., 1999), were
provided by K.-K. Conzelmann (Max-von-Pettenkofer Institut,
Munich, Germany) and grown in GMEM supplemented with 10%
TPB, 10% FCS and 1 mg G418 ml21. CPT-Tert cells (Arnaud et al.,
2010) are sheep choroid plexus cells immortalized with the simian
virus 40 T-antigen and human telomerase reverse transcriptase and
were kindly provided by Dr David Griffiths (Moredun Research
Institute, Edinburgh, UK); they were grown in Iscove’s modified
Dulbecco’s medium supplemented with 10% FCS. A549, Vero E6 and
HeLa cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FCS, and MDBK, MDCK, Hep2
and HuH7 cells were grown in DMEM containing 10% FCS and 1%
non-essential amino acids. All mammalian cell lines were grown at
37 uC with 5% CO2. A. albopictus C6/36 cells (Igarashi, 1978) were
maintained at 28 uC in Leibovitz 15 medium supplemented with
10%FCS and 10% TPB.
Viruses. The BH80/11-4 isolate of SBV was generously provided by Dr
Martin Beer (Friedrich-Loeffler Institute, Insel Reims, Germany) and
was propagated and plaque purified in BHK-21 cells using standard
procedures (Mazel-Sanchez & Elliott, 2012), as were recombinant SBVs
generated from cDNA clones. rBUNV and the NSs-deleted version,
rBUNVdelNSs2 (Hart et al., 2009), were grown and titrated in BHK-21
cells. Viruses were titrated by plaque assay in the different cell lines
under an overlay comprising GMEM supplemented with 2% NCS and
0.6% Avicell (FMC) and incubated at 37 uC for 3 days. Cell
monolayers were fixed with 4% formaldehyde and plaques were
visualized by staining with crystal violet.
Cloning of SBV cDNA. SBV was grown in BHK-21 cells at 37 uC
until a marked CPE was noted, and 1.75 ml clarified supernatant
medium was concentrated approximately tenfold using an Amicon
Ultra-15 centrifugal filter device (Millipore). RNA in the concentrated
sample was extracted using a QIAamp Viral RNA Mini kit according
to the manufacturer’s instructions, and the RNA was eluted in 60 ml
AVE buffer (Qiagen). First-strand cDNA was synthesized from 5 ml
RNA using 100 pmol segment-specific forward primer (Table S1) and
either Moloney murine leukemia virus (for the S segment; Promega),
Finzymes Phusion (for the M segment; New England Biolabs) or
Transcriptor (for the L segment; Roche) reverse transcriptase
according to the respective manufacturer’s instructions. Segment-
specific cDNAs were amplified by PCR using appropriate primer pairs
(Table S1) with optimized cycling conditions (available from the
authors on request) and KOD polymerase (for the S and L segments;
Merck) or Phusion polymerase (for the M segment; New England
Biolabs). Full-length PCR products were purified by agarose gel
electrophoresis, digested with BsmBI (S and M cDNA) or BfuAI (L
cDNA) and ligated into BbsI-linearized plasmid TVT7R(0,0)
(Johnson et al., 2000). The cDNA inserts included an extra G residue
at their 59 ends for efficient T7 transcription, and the inserts were
cloned such that T7 polymerase would transcribe antigenome-sense
RNAs. The plasmids were named pTVTSBVL, pTVTSBVM and
pTVTSBVS. To abolish NSs expression from the S segment, three
point mutations were introduced into pTVTSBVS (C96A, G106A and
T115A) using a QuikChange Site-directed Mutagenesis kit
(Stratagene) using primers SBdNSs3ST_FW and SBdNSs3ST_RV
(Table S1). These substitutions created in-frame translation stop
codons at positions 14, 17 and 20 in the NSs ORF (Fig. 2c), and the
plasmid was designated pTVTSBVS-delNSs3Stop.
Generation of recombinant viruses from cDNAs. Recombinant
viruses were produced using a three-plasmid rescue system (Lowen
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Fig. 6. IFN bioassay. A549 cells were infected with wtSBV,
rSBVdelNSs, wtBUNV or rBUNdelNSs at an m.o.i. of 1 and
incubated at 37 6C for 48 h. Twofold dilutions of the clarified and
UV-treated supernatant were used to treat fresh A549 cells in a
96-well plate for 24 h. The cells were then infected with EMCV
and the development of CPE was monitored at 48 h p.i. by staining
with crystal violet. The production of IFN was calculated according
to the highest dilution of supernatant giving protection against
EMCV infection and is expressed as relative IFN units. The
experiment was conducted twice and gave identical results.
Schmallenberg virus reverse genetics
http://vir.sgmjournals.org 857
et al., 2004). Subconfluent BSR-T7/5 cells (36105 cells per well of a
six-well plate) were transfected with 1 mg each of pTVTSBVL,
pTVTSBVM, and pTVTSBVS or pTVTSBVS-delNSs3Stop using 5 ml
Lipofectamine 2000 (Invitrogen) in a total volume of 500 ml
OptiMEM (Invitrogen). Transfected cells were incubated at 37 uC
and the supernatants were harvested when a marked CPE was
observed (5 days post-transfection). The rescue outcome was assessed
by plaque assay on BHK-21 cells. The genome segments of the
recovered viruses were amplified by RT-PCR and their nucleotide
sequences determined.
Antibodies. The coding sequence for SBV N was amplified by PCR
from pTVTSBVS with oligonucleotides SBV-N-SacI-tev and SBV-N-
r-XhoI (Table S1), and cloned into modified pDEST14 vector
(Invitrogen) using SacI and XhoI restriction sites, generating plasmid
p14SBVN. The N ORF has an N-terminal hexahistidine (6His) tag
and a tobacco etch virus protease site (for removal of the 6His tag).
Proteins were expressed in Escherichia coli BL-21 Rosetta 2 cells
(Merck) following induction with IPTG (1 mM final concentration)
at 20 uC for 16 h with shaking. Recombinant proteins were purified
by binding to Ni-NTA resin, eluted with 200 mM imidazole, 0.3 M
NaCl, 0.1 M Tris/HCl (pH 8.0), and concentrated into PBS contain-
ing 5% glycerol using a Vivaspin 20 centrifugal concentrator
(Sartorius AG). Purified proteins were used to generate polyclonal
rabbit antisera commercially (Eurogentec). Anti-tubulin antibody
(clone B512) was purchased from Sigma. Both antibodies were used
at a 1 : 5000 dilution in Western blotting experiments.
Viral protein synthesis. BHK-21 cells were infected at an m.o.i. of 3
p.f.u. per cell, incubated at 37 uC and cell lysates were prepared at
various times p.i. by the addition of 300 ml lysis buffer [100 mM Tris/
HCl (pH 6.8), 4% SDS, 20% glycerol, 200 mM DTT, 0.2%
bromophenol blue and 25 U ml21 Benzonase (Novagen)]. For
metabolic labelling, 35 mCi per well of TRANS35S-Label (MP
Biomedicals) in methionine-free DMEM was added and incubation
was continued for 2 h before harvest. Proteins were separated by SDS-
PAGE on a 4–12% acrylamide gel (Invitrogen). Thereafter, proteins
were transferred to Hybond-C membrane for Western blotting (as
described by Carlton-Smith & Elliott, 2012), or, for radiolabelled
proteins, the gel was fixed, dried and exposed to X-ray film.
Biological assay for IFN production. This assay was carried out
essentially as described by Mohamed et al. (2009). In brief, A549 or
CPT-Tert cells in 35 mm dishes were infected with the different viruses
at an m.o.i. of 1 and incubated at 37 uC for 48 h. Supernatant fluid was
clarified by centrifugation, residual virus was inactivated by UV
treatment, and twofold serial dilutions of the medium were applied to
fresh A549 or CPT-Tert cells grown in 96-well plates for 24 h. The cells
were then infected with EMCV, which is sensitive to IFN, and
incubated for 4 days at 37 uC. The cells were fixed with formaldehyde
and stained with crystal violet to monitor the development of CPE.
Based on the dilution affording protection against EMCV infection, the
relative amount of IFN produced was calculated.
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